← back to search

Varvara Polydoropoulou

Frontier Science Foundation-Hellas ·
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, and Breast Cancer Treatment Studies.
h-index
9
citations
922
works
18
NIH funding
primary concept
Medicine
email

Recent publications

A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Annals of Oncology 2020cited by 271position: middledoi
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Annals of Oncology 2019cited by 246position: middledoi
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Annals of Oncology 2019cited by 55position: middledoi
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project
Lung Cancer 2019cited by 48position: middledoi
Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project
Journal of Thoracic Oncology 2017cited by 84position: middledoi
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project
Annals of Oncology 2017cited by 50position: middledoi
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab
JAMA Oncology 2016cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

James Spicer · King's College London2 papers (2019–2020)Alessandra Curioni‐Fontecedro · University of Fribourg2 papers (2019–2020)Sanjay Popat · Royal Marsden NHS Foundation Trust2 papers (2019–2020)Solange Peters · Hôpital Beau-Séjour2 papers (2019–2020)Oliver Gautschi · University of Bern2 papers (2019–2020)Urania Dafni · Space Hellas (Greece)2 papers (2016–2020)Rafael López Castro · Universidad de Valladolid2 papers (2019–2020)A. Roy · Sylhet MAG Osmani Medical College2 papers (2019–2020)A. Pope · Clatterbridge Cancer Centre NHS Foundation Trust2 papers (2019–2020)P.M. Fisher · Sheffield Teaching Hospitals NHS Foundation Trust2 papers (2019–2020)Wolf-Dieter Janthur · Kantonsspital Aarau2 papers (2019–2020)Rosario García Campelo · Instituto de Investigación Biomédica de A Coruña2 papers (2019–2020)Mary O’Brien · Imperial College London2 papers (2019–2020)Rolf A. Stahel · International Breast Cancer Study Group2 papers (2019–2020)Ernest Nadal · Universitat de Barcelona2 papers (2019–2020)Sylvie Rusakiewicz · University Hospital of Lausanne2 papers (2019–2020)Heidi Roschitzki‐Voser · International Breast Cancer Study Group2 papers (2019–2020)David Gilligan · University of Cambridge2 papers (2019–2020) · 2 papers (2016–2019)Barbara Ruepp · Frontier Science Foundation-Hellas2 papers (2019–2020)